{
    "nct_id": "NCT06215430",
    "official_title": "A Phase I, Open-label, Fixed-sequence, Drug Interaction Study to Investigate the Effect of Multiple Oral Doses of LOXO-305 on CYP1A2, CYP2C9, and CYP2C19 Substrates Using a Probe Drug Cocktail in Healthy Subjects",
    "inclusion_criteria": "* Must have Body mass index (BMI) within the range of 18.0 to 32.0 kilograms per square meter (kg/m^2), inclusive.\n* Male and female participants in good health, determined by no clinically significant findings from medical history, 12-lead Electrocardiogram (ECG), vital sign measurements, or clinical laboratory evaluations as assessed by the investigator.\n* Female participants of non-childbearing potential and male participants who follow standard contraceptive methods.\n* Must have comply with all study procedures, including the 23-night stay at the Clinical Research Unit (CRU) and follow-up phone call.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 55 Years",
    "exclusion_criteria": "* History or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor.\n* Known ongoing alcohol and/or drug abuse within 2 years prior to Screening.\n* History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).",
    "miscellaneous_criteria": ""
}